Background
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in persons aged 65 years and older and the sixth leading cause of death in the United States [1] . Total healthcare payments in 2014 for people aged 65 years and older with dementia are estimated at $214 billion [1] . By the middle of the century, the number of Americans with AD is projected at 13.8 million with one new case developing every 33 seconds or almost one million new cases per year. The global burden of AD or dementia in 2015 is more daunting with new cases of dementia in every 3 seconds, and the estimated worldwide costs of dementia are about $818 billion, rising to $2 trillion by 2030 [2] . The number of people living with dementia in 2015 is estimated to be 9.4 million in the Americas, 10.5 million in Europe, 4.0 million in Africa, and 22.9 million in Asia [2] . This is a tremendous global epidemic in elderly persons regardless of ethnic background.
AD with onset age after 65 years is highly heritable with an estimated 74% of the liability explained by genetic factors [3] . A major genetic Q3 risk factor for AD is APOE genotype [4] that accounts for approximately 35% of the genetic variance [5] . The three common APOE alleles ( 32, 33, and 34) are determined by combinations of polymorphic amino acid residues at Arg112 (rs429358) and Cys158 (rs7412) [6] . Among non-Hispanic whites of European ancestry (EA), 34 heterozygotes have a 2.5-to 3.0-fold increased risk and 34 homozygotes have a 10-to 12-fold increased risk, compared with persons with the 33/ 33 genotype [4] . The 32 allele is protective [7] such that carriers of this allele have a 40% reduction in AD risk compared with 33/ 33 individuals [4] . The effect of APOE genotype to AD risk is highly variable in other populations. The 34 frequency is lower in Asians [8] and associated with higher AD risk among Japanese (JPN) compared with EAs [9] . In contrast, the effect of 34 on AD risk is much less in African-Americans (AAs) among whom the 34 frequency is about 50% higher than in EAs [10] . It is noteworthy that the 34 allele is virtually absent among Arabs living in northern Israeli community where the prevalence of dementia is roughly double than in EA populations [11] .
More than 20 loci have been robustly associated with AD [12] and are enriched in immune response, regulation of endocytosis, cholesterol transport, and protein ubiquitination pathways [13] . A recent genome-wide association study (GWAS) identified significant association of AD with multiple single-nucleotide polymorphisms (SNPs) in the MAPT-KANSL1 region among EAs lacking an APOE ε4 allele [14] . Genetic studies in other populations have increased our understanding of the genetic architecture of AD. For example, the effect of the APOE 34 allele is much greater in JPN and substantially weaker in AA and some Hispanic groups, due in part to varying frequencies of this allele across populations [4] . Three loci (SORL1, ABCA7, and ACE) whose association with AD attained genome-wide significance in EAs [12] were found to have larger effects on AD risk in AAs (ABCA7) [15] , JPN (SORL1) [9] , and Israeli-Arabs (IAs) (ACE) [16] . Some loci including PLXNA4 [17] and SORL1 [18] demonstrate allelic heterogeneity among genetically diverse populations. In the present study, we leveraged genetic diversity across ethnic groups to increase discovery of additional AD risk loci by combining GWAS results obtained from samples of EAs, AAs, JPN, and IAs.
Methods

Subjects, genotyping, and data processing
Details of subject recruitment and genotyping for individual case-control and family-based datasets, genotype imputation, quality control, population substructure, and statistical methods for association analyses were reported previously for Alzheimer's Disease Genetics Consortium (ADGC) datasets containing EAs [5] , AAs [15] , JPN [9] , and IAs [11] . Characteristics of the 33,269 ADGC subjects (26,320 EAs, 4983 AAs, 1845 JPN, and 115 IAs) 1.74-3.78 , respectively. GRRs of ,5 are not detectable with 80% power in the small IA sample. However, the goal of this study was not for novel discovery within ethnic groups but rather in the total transethnic sample. Prompted by findings of the previous studies [14] , we also conducted separate GWAS in subgroups of subjects who have or lack an APOE ε4 allele. We also applied a complementary approach for assessing a differential effect of association by APOE genotype by evaluating association of AD with an interaction of SNP and ε4 status.
SNP-based association
Within each dataset, genome-wide association analyses were conducted using more than 7 million imputed SNPs in the total sample and in subgroups of subjects with and without the APOE ε4 allele, using regression models including age, sex, and the first three PCs. An additive effect of a SNP was included in the model as a quantitative estimate between 0 and 2 representing the probability score of the effect allele to incorporate the uncertainty of the imputation estimates. Models were evaluated using a logistic generalized linear model in case-control datasets and a logistic generalized estimating equation in family-based datasets. We also evaluated models including a term for the interaction of the SNP dosage with the APOE ε4 status and models among subgroups stratified by APOE ε4 status. Results for each model across datasets were combined by metaanalysis separately within each ethnic group using a fixedeffects, inverse-variance weighted meta-analysis in the METAL program [19] . SNPs with a minor allele frequency 1% and imputation quality 0.4 that were available in at least 50% of the datasets were included in the metaanalysis. The meta-analysis P-value for association was estimated by the summarized test statistic, after applying genomic control within each individual study. Metaanalysis was also conducted using Han and Eskin-modified random-effects (RE-HE) model that is optimized to detect associations under effect heterogeneity, as implemented in METASOFT [20] . This model has similar power to the fixed effects model when heterogeneity is modest, for example, when the standard deviation of the different ethnicities log odds ratios (ORs) is 0.5 times the mean log OR, but has better power than the fixed effects model for substantial heterogeneity. Thus, we do not expect the RE-HE model to produce substantially different results from the fixed effects 244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310   311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376 model unless substantial heterogeneity among ethnicities exists.
Gene-based association
We conducted genome-wide gene-based tests using ethnic-specific association results from SNP-based tests. Intragenic SNPs and SNPs within 30 kilobases (kb) of transcription start and stop sites were included in each genebased test. We used the GATES [21] method, which computes a gene-based P-value using SNP-based P values and SNP-SNP correlations by penalizing lack of association in correlated SNPs. Ethnic-specific gene-based results for EA, AA, JPN, and IA groups were combined using the sample-size weighted Z-score method in METAL assuming the same direction of effect.
Follow-up association analysis
In Stage 2, we attempted to replicate Stage 1 topranked SNP-based (P , 10 25 ) results and validate genebased (P , 10 24 ) results from each ethnic subgroup. Previously known AD genes were evaluated in Stage 2 only when both SNP-based and gene-based P values met threshold criteria for follow up. These analyses incorporated summarized results for the Stage 2 ADGC datasets and previously reported results for IGAP datasets excluding those from the ADGC that are described in Supplementary Table 1 . The genome-wide significance threshold was set at P , 5 ! 10 28 for individual SNPs and P , 2 ! 10 26 for gene-based tests in the Stage 1 1 2 analyses.
Results
Findings with individual SNPs
There was little evidence for genomic inflation in SNPbased GWA results in the total sample with main effect (l 5 1.02) and interaction effect of an SNP with APOE ε4 status on AD risk (l 5 1.02) and in APOE ε41 subjects (l 5 0.99) and APOE ε4-subjects (l 5 0.99) ( Supplementary Fig. 1 ). In the total sample, we confirmed genome-wide significant (GWS) association (P , 5 ! 10 28 ) with SNPs in several previously implicated AD loci including CR1, BIN1, PTK2B, MS4A2/MS4A6A, PICALM (Supplementary Table 2 and Supplementary Fig. 2 ). GWS association was also observed with SNPs in NFIC and PRKCE through interaction with APOE ( Supplementary  Fig. 2B ) and with SNPs between USP6N and ECHDC3 among subjects lacking APOE ε4 ( Supplementary  Fig. 2D ). Top-ranked SNPs in EA for PICALM, SORL1, and ABCA7 had strong support for association in JPN, whereas the top-ranked SNPs in CR1, BIN1, and EPHA1 were consistently associated in EAs and AAs (Supplementary Table 2 ). In contrast, the effect direction was significantly opposite in EAs versus AAs for NME8, ABCA7, and CASS4 SNPs (Supplementary Table 2 ). A total of 35 SNPs from 9 novel loci met criteria for follow up in Stage 2 (Supplementary Table 3 ). Extensive evaluation of SNPs from the APOE region across the different ethnic groups demonstrated that only the APOE ε2 SNP (rs7412) remained genome-wide significant among APOE ε4-subjects (Supplementary Table 4 ), confirming our prior observation that APOE accounts for all association signals in this region [22] . SNPs in other loci showed suggestive evidence for association (P , 10 26 ) in EAs or AAs (Supplementary Table 5 ), but these results were much less significant in the transethnic meta-analyses. Analysis of models including an interaction term for each SNP with APOE ε4 status identified a GWS significant interaction (interaction: P 5 1.5 ! 10 28 ) for NFIC SNP rs9749589 (Table 1 ). This SNP appeared protective in 341 subjects (OR 5 0.83, P 5 6.4 ! 10 26 ) but slightly increased risk of AD in 34-subjects (OR 5 1.11, P 5 6.0 ! 10 23 ) (Supplementary Table 6 ). In the combined Stage 1 1 2 sample, GWS association was observed with SNPs in several previously established AD loci (CR1, BIN1, PTK2B, MS4A4A, and PICALM) Fig. 3 and Supplementary Fig. 4 ). Follow-up of the 35 SNPs from novel loci in Stage 2 revealed nominally significant associations for nine SNPs in PFDN1/HBEGF, USP6NL/ECHDC3, and BZRAP1-AS1 (Supplementary Table 6 ). In the combined Stage 1 1 2 sample, GWS association was attained with two intergenic SNPs between PFDN1 and HBEGF (best SNP: rs11168036, P 5 7 ! 10 29 ), six intergenic SNPs between USP6NL and ECHDC3 (best SNP: rs7920721, P 5 3 ! 10 28 ), and BZRAP1-AS1 SNP rs2632516 (P 5 4 ! 10 28 ) ( Table 1 , Fig. 1 , and Supplementary Table 6 ). Analyses of models that conditioned on the top SNP at the PFDN1/HBEGF, USP6NL/ ECHDC3, and BZRAP1-AS1 loci confirmed a single association signal in each region ( Supplementary Fig. 5 ). The significant interaction between NFIC SNP rs9749589 and 34 status in Stage 1 was not significant in Stage 2 (P 5.2); however, the magnitude and direction of effect were the same, and the interaction P value in the total sample was not diminished (Table 1 and Fig. 1 ). These GWS associations, except for rs7920721, were supported by evidence in multiple ethnic groups (Fig. 2) . Further evaluation of the Stage 1 1 2 findings revealed that the association with the USP6NL/ECHDC3 SNPs was exclusive to subjects lacking APOE 34 (e.g., rs7920721: 341, P 5 .07, OR 5 1.05; 342, P 5 2.7 ! 10 29 , OR 5 1.14; interaction P 5 .01) and comparable in terms of effect size and direction in the non-EA groups (Supplementary Table 6 and Supplementary Fig. 6 ). All GWS findings were similar using the METASOFT RE-HE model (Supplementary Table 7 ).
Gene-based test findings
In Stage 1 analyses, there was strong evidence of association (gene-based P , 10 24 ) with previously established loci and novel loci in the total sample (Supplementary Fig. 7 and Supplementary Table 8) but only seven known genes (CR1, BIN1, PTK2B, CLU, MS4A4A, PICALM, and ABCA7) and one novel one (TPBG) were GWS (P , 2.7 ! 10 26 ) in the combined Stage 1 1 2 sample (Table 2 and Supplementary  Table 8 ). Both EAs and AAs contributed to the association with TPBG. No additional genes were identified as GWS in interaction models or APOE genotype subgroups.
Discussion
In this large transethnic genetic study of AD, we identified robust associations with several novel loci at the individual SNP level (PFDN1/HBEGF, USP6NL/ECHDC3, BZRAP1-AS1, and NFIC) and gene level (TPBG) in a sample of AD subjects and cognitively normal elders in cohorts containing whites of EAs, AAs, JPN, and IAs. Most of these findings are supported by evidence in more than one ethnic group (Fig. 2 and Table 2 ). Previous GWAS using the EA discovery cohorts in this study did not detect genome-wide significant association with any of these loci, although there was suggestive evidence of association (P . 10 27 ) for the top SNPs in the PFDN1/HBEGF and USP6NL/ECHDC3 regions in EAs [12, 14] . The other novel genes identified in this study were not previously reported to be associated with AD in any ethnic groups. The association with SNPs in the USP6NL/ECHDC3 region was specific to persons lacking the APOE ε4 allele. Our study also showed that associations for several genes that have previously been robustly implicated in AD in Caucasians of European descent (CR1, BIN1, PTK2B, MS4A4A, and PICALM) were evident in other populations even at the SNP level.
HBEGF, heparin
Q5
EGF-like growth factor, has roles in wound healing, cardiac hypertrophy, and heart development [23] . Although the biological role for this gene in AD is not obvious, an HBEGF knockout mouse that does not express HBEGF in cortex and hippocampus has psychiatric and cognitive dysfunctions that accompany downregulated N-methyl-D-aspartate receptors [24] . Another study showed that rats exposed to the pesticide cypermethrin had a reduction of HBEGF expression leading to upregulation of GSK3b-dependent Ab and phosphorylated tau [25] .
A recent GWAS demonstrated pleiotrophic effects of SNPs in the USP6NL/ECHDC3 (including rs7920721) and BZRAP1-AS1 loci for AD and plasma C-reactive protein and lipid levels [26] . The pleiotropy at USP6NL/ ECHDC3 may be related to the association finding at this locus among persons lacking the APOE 34 allele. USP6NL, ubiquitin-specific peptidase 6 N-terminal like, has a role in the EGF receptor (EGFR) signaling pathway by acting as a GTPase-activating protein and inhibiting internalization of EGFR [27] . Insight for a role of USP6NL may be gained from information about USP6 that regulates ubiquitylation and trafficking of cargo protein by clathrinindependent endocytosis [28] . There is a growing body of evidence from studies in humans and mice supporting a role for clathrin-mediated endocytosis in AD [29] [30] [31] . In addition, the association of the phosphatidylinositolbinding clathrin assembly protein (PICALM) gene to AD is well established [12] .
ECHDC3, enoyl CoA hydratase domain containing 3, is involved in fatty acid biosynthesis in mitochondria, and its expression is increased in patients with acute myocardial infarction [32] . It has been observed that ECHD3 expression is altered in brains from persons with AD compared with controls [26] . Although rs7920721 is closer to ECHDC3 than USP6NL, it is located on USP6NL side of a recombination hotspot between these two genes (Fig. 1B) . Therefore, we cannot rule out either of these genes, or even one not adjacent to rs7920721, as explaining the association signal in this region.
BZRAP1, benzodiazepine-associated protein 1 (renamed as TSPO-associated protein 1, TSPOAP1), is a subunit of the benzodiazepine receptor complex in 512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578   579  580  581  582  583  584  585  586  587  588  589  590  591  592  593 mitochondria and a marker of neuroinflammation [33] . A recent prospective cohort study of 8240 individuals aged 65 years and older showed an increased risk of dementia with use of long half-life benzodiazepines [34] , a drug often prescribed for treatment of anxiety. A TSPO ligand (Ro5-4864) has been shown to reverse b-amyloid accumulation and behavioral impairment in 3xTgAD mice [35] . A recent positron-emission tomography imaging study demonstrated that the change over time of TSPO binding to radioligand 11C-PBR28 is correlated with progression of AD [36] . The relationship of AD to the other novel loci identified in this study is less clear. PFDN1, a prefoldin subunit, is upregulated in colorectal cancer [37] . NFIC is a CCAAT-binding transcription factor. A study comparing brain gene expression profiles between HIV seropositive individuals with cognitive impairment and AD cases identified NFIC as having significant high co-expression connectivity in white matter [38] . Trophoblast glycoprotein (TPBG), also known as 5T4, regulates development of the olfactory bulb GABAgenic interneurons and its overexpression in newborns is associated with abnormal dendrites [39] .
Our study highlights the benefit of combining results obtained from genetically diverse populations. The transethnic approach applied here identified three novel loci (BZRAP1-AS1, NFIC, and TPBG) and GWS association for the first time with two other loci (PFDN1/HBEGF and USP6NL/ECHDC3) noting that the size of the discovery sample in this study was less than 45% of the one included in a previous GWAS that contained more than 74,000 EA subjects. The improved power in our smaller sample can be ascribed to allele frequency differences and allelic heterogeneity among the ethnic groups. Abbreviations: CH, chromosome; EA, European ancestry; AA, African-American; JPN, Japanese; IA, Israeli-Arab; P, gene-based P-value.
web 4C=FPO web 4C=FPO As an example highlighting the importance of these differences, the top SNPs from BZRAP1-AS1 and NFIC had different minor allele frequencies across ethnic groups, but the effect sizes were similar and association signals were greater in fixed-effect meta-analysis. In addition, gene-based tests, which consider association patterns with all SNPs in the locus, identified TPBG. Importantly, the most significant SNPs in these two regions differed among the ethnic groups. Gene-based tests also indicated potential allelic heterogeneity among ethnic groups for previously established AD genes including TREM2 and ABCA7. The novel GWS SNP associations were robust in analyses allowing for heterogeneity across different ethnic groups, and the P-values for the RE-HE approach were slightly larger than for the fixed-effect model, suggesting that the effect size heterogeneity across the groups is modest. Our study also revealed that the effect direction for several SNPs vary across ethnic groups. For example, the top-ranked SNPs in NME8, ABCA7, and CASS4 (Supplementary Table 2 ) were nominally significant in EAs and AAs, but the referent allele was associated with increased risk in one group and decreased risk in the other. One explanation for these differences is that the SNPs are tagging different functional variants across groups. This idea is consistent with our findings from gene-based tests showing that the constellation of variants contributing to the association with some genes was different across ethnic groups. Alternatively, when examining a large number of variants, it is expected that a few will show nominal significance in opposite directions among groups.
There are several limitations associated with our study. The sample size imbalance between the EAs and the other populations weakened the opportunity to identify association patterns that may be unique to the non-EA groups. The small size of the non-EA groups also reduced power to detect novel gene associations if the functional variants (and the SNPs that tag them) differ among ethnic groups. An additional weakness is the lack of replication samples for the non-EA populations. Despite these limitations, our study highlights the importance of investigating the genetic architecture for AD in ethnically diverse populations.
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